Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections

Canadian Journal of Ophthalmology

Volumn 47, Issue 3, 2012, Pages 275-279

  Sharma, Sanjay ^a   Johnson, Davin ^a   Abouammoh, Marwan ^a,b   Hollands, Simon ^a   Brissette, Ashley ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOPHTHALMITIS; EYE DISEASE; EYE INFLAMMATION; FEMALE; HEART INFARCTION; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RETINA DETACHMENT; STROKE; UNSPECIFIED SIDE EFFECT; VITREOUS HEMORRHAGE;

EID: 84862276053     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2012.03.026     Document Type: Article

References (35)

1. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-908.
2. Outbreak of acute intraocular inflammation after bevacizumab intravitreal injection: An epidemiological investigation. Canadian Ophthalmology Society Annual Conference and Exhibition. 2009; Toronto.
3. Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93:457-62.
4. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2008; 115:1911-5.
5. Yamashiro K, Tsujikawa A,Miyamoto K, et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina. 2010;30:485-90.
6. Sato T, Emi K, Ikeda T, et al. Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology. 2010;117:512-6.
7. Ness T, Feltgen N, Agostini H, et al. Toxic vitritis outbreak after intravitreal injection. Retina. 2010;30:332-8.
8. Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: A retrospective cohort study. Can J Ophthalmol. 2010;45: 239-42.
9. Fielden M, Nelson B, Kherani A. Acute intraocular inflammation following intravitreal injection of bevacizumab: A large cluster of cases. Acta Ophthalmol. 2011;89:e664-5.
10. Chong DY, Anand R, Williams PD, et al. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina.2010;30:1432-40.
11. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232-9. (Pubitemid 47299901)
12. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for agerelated macular degeneration. Arch Ophthalmol. 2010;128:1273-9.
13. Chang TS, Kokame G, Casey R, et al. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration. Retina. 2009;29:1235-41.
14. Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: Our experience after 2,000 injections. Retina. 2009;29:313-8.
15. Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2009;223:370-5.
16. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: A multicenter, retrospective study. Ophthalmology. 2010;117:298-302.
17. Gamulescu MA, Radeck V, Lustinger B, et al. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. Int Ophthalmol. 2010;30:261-6.
18. Gharbiya M, Giustolisi R, Allievi F, et al Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab: A randomized controlled trial. Am J Ophthalmol. 2010;149:458-64 e1.
19. Subramanian ML, Ness S, Abedi G, et al Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective dou- ble-masked, randomized clinical trial. Am J Ophthalmol. 2009;148: 875-82.
20. Mezad-Koursh D, Goldstein M, Heilwail G, et al. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina. 2010;30:1051-7.
21. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246:779-81.
22. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-44. (Pubitemid 44511558)
23. Aucte intraocular inflammation following intravitreal injection of bevacizumab- a cluster of cases. Canadian Ophthalmology Society Annual Conference and Exhibition. 2009; Toronto.
24. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structureimmunogenicity relationships of therapeutic proteins. Pharmacol Res. 2004;21:897-903.
25. Banai S, Shweiki D, Pinson A, et al. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: Implications for coronary angiogenesis. Cardiovasc Res. 1994;28:1176-9. (Pubitemid 24264723)
26. Zhang Z, Chopp M. Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. Trends Cardiovasc Med. 2002;12:62-6. (Pubitemid 34154852)
27. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-5.
28. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309-12. (Pubitemid 20066717)
29. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest. 2000;106:829-38.
30. Wang YQ, Guo X, Qiu MH, et al. VEGF overexpression enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral artery occlusion. J Neurosci Res. 2007;85:73-82. (Pubitemid 46079798)
31. Sun Y, Jin K, Xie L, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest. 2003; 111:1843-51. (Pubitemid 38057729)
32. Wang Y, Jin K, Mao XO, et al. VEGF-overexpressing transgenic mice show enhanced post-ischemic neurogenesis and neuromigration. J Neurosci Res. 2007;85:740-7. (Pubitemid 46426073)
33. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-82. (Pubitemid 350181137)
34. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855-9. (Pubitemid 46635858)
35. Wong TY, Klein R, Sun C, et al. Age-related macular degeneration and risk for stroke. Ann Intern Med. 2006;145:98-106. (Pubitemid 46780583)